We preliminarily speculated that leonurine promotes the expression of ADRA1a, phosphorylates and activates the AMPK signaling pathway, decreases the expression of SCD1, and decreases the levels of GPs and FAs in liver, thereby exerting its anti-NAFLD effect. This evidence concerns the gene ADRA1A and metabolic dysfunction-associated steatotic liver disease.